Iantrek
PrivateLast Round
Growth Equity
Apr 28, 2026
Total Funding Raised
$72M
Momentum Score
75 /100
Company Overview
Iantrek, Inc. is a venture-funded ophthalmic medical technology company founded in 2019 by Dr. Sean Ianchulev. The company focuses on developing and commercializing micro- and bio-interventional solutions to advance the surgical treatment of chronic eye diseases, with a primary focus on glaucoma. Its product portfolio includes the AlloFlo Uveo, AlloSert Uveo, and C.Rex devices, which are designed to improve surgical precision and access the eye's natural outflow pathways. Iantrek aims to address unmet needs in glaucoma care by providing new, minimally invasive surgical options. The company is headquartered in White Plains, New York, and has raised significant venture funding to support the U.S. commercial launch of its products.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iantrek Comps
Public and private peers based on sector, stage, and business model.
Iantrek Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Apr 28, 2026 | ||||
| Series C | Aug 20, 2025 |
Key People
Founding team and executive leadership
Iantrek Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Venture Partners | Series C |
| aMoon | Series C |
| Radius Special Situations Fund | Series C |
| Trinity Capital | Growth Equity |
| Sectoral | Series C |
| Visionary Ventures | Series C |
| Civilization Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
$30M round led by Trinity Capital.
- Mar 31, 2026
Introducing AlloSpan Canal, a bio-reinforced platform for ophthalmic surgery.
Iantrek Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Iantrek's valuation, stock price, and market status.
